top of page
HM.BioConsulting
SPOTLIGHTS
SPOTLIGHTS
News and Insights to Biotech and Innovation.
Read Key Thought Leader opinions, promotional highlights, marketing insights, and curated updates from the life sciences world, all through the lens of business development consulting.
HM.BioConsulting Consortium shares scientific advancements with commercial impact, and spotlights innovations driving growth across the biotech and pharma landscape.
Australia's New Approach Methodologies Advantage
HM.BioConsulting Spotlight Series ISSUE 10-1 · MAY 2026 A Strategic Intelligence Report by Henning Mann, HM.BioConsulting, Emma Aitken, Australian Trade & Investment Commission, Michael Phelan, InnovApproach Consulting Prepared by Henning Mann, PhD | Founder & Principal, HM.BioConsulting May 2026 Get the Full Article PDF EXECUTIVE SUMMARY Australia has quietly become a powerful launchpad for early-phase clinical development, and a rising hub for New Approach Meth
Henning Mann
May 2713 min read
Fixing Clinical Trial Matching - From Bottleneck to Breakthrough
A Conversation between Rebecca Clyde, PhD, Botco.ai, and Henning Mann, PhD, HM.BioConsulting Authors: Rebecca Clyde, Desiree Goubert, Henning Mann Clinical trial matching is entering a new phase where advanced AI is embedded directly into clinical workflows, enabling a meaningful shift in speed and accessibility. In a recent discussion with Rebecca Clyde, Co-founder and CEO of Botco.ai, we discussed how this approach connects patients, physicians, and trial sponsors while red
Henning Mann
Apr 269 min read
From Moon to Market: When New Approach Methodologies Cross the Threshold
A Reflection by Désirée Goubert, PhD, & Henning Mann, PhD; HM.BioConsulting Download PDF here: There is something quietly profound about the idea that human tissue models have now travelled beyond low Earth orbit, circled the moon, and returned. As a first, not as a vision or grant proposal, let alone a symbolic gesture, but indeed as working and applied biological systems designed to answer a very practical question: how does the human body respond to extreme environments?
Henning Mann
Apr 154 min read
Synergy, Not Substitution: How Organ-on-Chip and Digital NAMs Unite for Translational Impact
Christian Maass, PhD, Principal Scientist & Lead, MPSlabs, ESQLabs GmbHHenning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir Applied Sciences, Nortis, Inc. Download the full article: Overview Over the past decade, Organ-on-Chip (OoC) platforms have matured into powerful microphysiological systems (MPS) capable of recapitulating dynamic human cellular microenvironments. Yet, widespread adoption in pharmaceutical and regulatory workflows has lagged, in many case
Henning Mann
Dec 15, 202511 min read
From Worms to Workstreams: How Ora Biomedical Is Scaling AI Driven Longevity Discovery
Mini StartUp Review & Example for Fractional BD Opportunity By Henning Mann, PhD | HM.BioConsulting 3–5 minute read Download the File “Longevity research is evolving. AI and automation are accelerating drug discovery. In this space Ora Biomedical is one to watch.” Background: Aging as a Modifiable Endpoint Aging is the single greatest risk factor for most chronic diseases, yet for decades, drug discovery pipelines have focused on treating symptoms rather than addressing upstr
Henning Mann
Nov 18, 20253 min read
Organ-on-Chip in 2025: AIM Bio In the Spotlight After the Regulatory Push
Download the article: A conversation between Elizabeth (Lizzy) Crist, Business Development Manager & Technical Lead (USA), AIM Biotech and Henning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir. Applied Science, Nortis Inc., Executive Intro With the FDA, NIH, and GAO each advancing the shift toward human-based preclinical models , Organ-on-Chip (OoC) and broader Microphysiological Systems (MPS) technologies have been moved into the spotlight and given unprecede
Henning Mann
Nov 4, 202517 min read
Capital Discipline in 2025: How Emerging Biotechs Can Thrive in a Constrained Funding Market
Review Opinion: Henning Mann, PhD, HM.BioConsulting LLC Download PDF: The more conversations we have with clients and prospects, the more...
Henning Mann
Sep 30, 20256 min read
Why Now Is the Time for Organ-on-Chip Companies to Step Up and Lead the Human-Based Research Revolution
Henning Mann, PhD, HM.BioConsulting 🚨 The Policy Shift We've Been Waiting For In 2025, the FDA, in collaboration with the National...
Henning Mann
Jul 22, 20254 min read
Article: Why Contract (Fractional) Business Development Is a Game Changer for Emerging Companies
Opinion, Henning Mann, PhD, HM.BioConsulting In today’s tight funding climate and intense competitive pressure, emerging and...
Henning Mann
Jul 22, 20253 min read
bottom of page